Jillian Clare Cohen
Dados Biográficos
| ID | 5408751 |
|---|---|
| NOME | Jillian Clare Cohen |
| PRENOMES | Jillian Clare |
| SOBRENOME | Cohen |
| ASSINATURA | COHEN J C |
| AFILIAÇÕES | Northeastern University |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 4 |
| TOTAL DE CITAÇÕES | 1 |
| TOTAL COMO AUTOR | 4 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2002 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2006 |
| ÍNDICE H | 1 |
Expanding Drug Access in Brazil
Pushing the Borders
W ^hen we think about drug access issues, typically we turn to the appalling lack of access in developing countries where, as the World Health Organization reports, one-third of the population does not have regular access to needed medicines. But the issue of drug access has also recently become a politically charged topic in the United States, the world's most lucrative pharmaceutical market. There have been several populist initiatives to buy p…
The Dilemma of Intellectual Property Rights for Pharmaceuticals
In this paper, we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally. Second, we explain how specific pharmaceutical policy tools can help developing states mitigate the worst effects of the TRIPS Agreement. Third, we put forward solutions that could be implemented by the World Bank to help overcome the divide between creating private incentives for researc…
Improving Transparency in Pharmaceutical Systems
This study presents a diagnostic \n framework and methodology to evaluate a pharmaceutical \n system s vulnerability to corruption and to determine which \n corrupt practices can have a major impact on the system s \n ultimate efficiency. We thus provide: (a) a systematic and \n quantifiable assessment of the extent to which a country s \n pharmaceutical system is vulnerable to corrupt practices; \n and (b) the identification of potential actions…
Improving Transparency in Pharmaceutical Systems
This study presents a diagnostic \n framework and methodology to evaluate a pharmaceutical \n system s vulnerability to corruption and to determine which \n corrupt practices can have a major impact on the system s \n ultimate efficiency. We thus provide: (a) a systematic and \n quantifiable assessment of the extent to which a country s \n pharmaceutical system is vulnerable to corrupt practices; \n and (b) the identification of potential actions…
The Dilemma of Intellectual Property Rights for Pharmaceuticals
In this paper, we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally. Second, we explain how specific pharmaceutical policy tools can help developing states mitigate the worst effects of the TRIPS Agreement. Third, we put forward solutions that could be implemented by the World Bank to help overcome the divide between creating private incentives for researc…
Pushing the Borders
W ^hen we think about drug access issues, typically we turn to the appalling lack of access in developing countries where, as the World Health Organization reports, one-third of the population does not have regular access to needed medicines. But the issue of drug access has also recently become a politically charged topic in the United States, the world's most lucrative pharmaceutical market. There have been several populist initiatives to buy p…
Expanding Drug Access in Brazil
Business (4 obras) · Pharmaceutical Economics and Policy (4 obras) · Computer Science (3 obras) · Law (3 obras) · Political science (3 obras) · Dilemma (2 obras) · Economic growth (2 obras) · Economics (2 obras) · TRIPS architecture (2 obras) · Access to medicines (1 obras)